Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Jaktinib in Hepatic Impairment
NCT04993404Phase 1Completed
- Sponsor
- Zelgen
- Start
- Aug 2021
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of jaktinib in myelofibrosis (MF) (4 arms), sponsored by Zelgen. Primary endpoints: Area Under the Curve From Time Zero to Last Quantifiable Concentration at Day 3, Maximum Observed Plasma Concentration at Day 3 and 1 more. Started Aug 2021; status: completed.
02
Drugs
jaktinib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT04993404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04993404.